Antihypertensive, sympatholytic and renal effects of an orally active dopamine agonist, RS-12254
McClelland, D.L.; Rosenkranz, R.P.
Proceedings of the Western Pharmacology Society 34: 135-140
1991
ISSN/ISBN: 0083-8969 PMID: 1686322 Document Number: 368060
Document emailed within 1 workday
Related Documents
Bergström, G.; Evans, R.G. 1998: Effects of renal medullary infusion of a vasopressin V1 agonist on renal antihypertensive mechanisms in rabbits American Journal of Physiology 275(1): R76-R85Abe, Y.; Miura, K.; Imanishi, M.; Yukimura, T.; Komori, T.; Okahara, T.; Yamamoto, K. 1980: Effects of an orally active converting enzyme inhibitor (YS-980) on renal function in dogs Journal of Pharmacology and Experimental Therapeutics 214(1): 166-170
Hahn, R.A.; MacDonald, B.R.; Martin, M.A. 1983: Antihypertensive activity of LY141865, a selective presynaptic dopamine receptor agonist Journal of Pharmacology and Experimental Therapeutics 224(1): 206-214
Laffan, R.J.; Goldberg, M.E.; High, J.P.; Schaeffer, T.R.; Waugh, M.H.; Rubin, B. 1978: Antihypertensive activity in rats for SQ 14,225, an orally active inhibitor of angiotensin I-converting enzyme Journal of Pharmacology and Experimental Therapeutics 204(2): 281-288
Jacob, B.G.; Richter, W.O.; Schwandt, P. 1993: Effect of three antihypertensive drug groups on lipid metabolism. Effects of alpha receptor blockers, central sympatholytic drugs and vasodilators Fortschritte der Medizin 111(8): 126-129
Aono, J.; Koga, T.; Yamazaki, T.; Shiraki, Y.; Sakai, K. 1988: Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril Archives Internationales de Pharmacodynamie et de Therapie 292: 203-222
Campanacci, L.; Bellini, G.; Battilana, G.; Rigoni, A.; Cosenzi, A.; Carretta, R.; Puppis, E.; Pierini, B.; Faccini, L. 1984: Central alpha-adrenergic agonist antihypertensive drugs and renal failure La Clinica Terapeutica 109(4): 301-309
Trugman, J.M.; Arnold, W.S.; Touchet, N.; Wooten, G.F. 1989: D1 dopamine agonist effects assessed in vivo with [14C]-2-deoxyglucose autoradiography Journal of Pharmacology and Experimental Therapeutics 250(3): 1156-1160
Arnerić, S.P.; Long, J.P.; Williams, M.; Goodale, D.B.; Mott, J.; Lakoski, J.M.; Gebhart, G.F. 1983: RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist Journal of Pharmacology and Experimental Therapeutics 224(1): 161-170
Onclin, K.; Silva, L.D.; Donnay, I.; Verstegen, J.P. 1993: Luteotrophic action of prolactin in dogs and the effects of a dopamine agonist, cabergoline Journal of Reproduction and Fertility. Supplement 47: 403-409
Hahn, R.A.; Wardell, J.R.; Sarau, H.M.; Ridley, P.T. 1982: Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist Journal of Pharmacology and Experimental Therapeutics 223(2): 305-313
Malmberg; Mikaels; Mohell, N. 1998: Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding Journal of Pharmacology and Experimental Therapeutics 285(1): 119-126
Carratù, M.R.; De Serio, A.; Lagioia, R.; Conte-Camerino, D.; Ferrari, E.; Mitolo-Chieppa, D. 1990: Effects of the partial dopamine receptor agonist, terguride, on the field-stimulated vas deferens in the mouse Bollettino della Societa Italiana di Biologia Sperimentale 66(1): 35-42
Hahn, R.A.; MacDonald, B.R. 1984: Systemic hemodynamic and regional blood flow effects of LY141865, a selective dopamine receptor agonist Journal of Pharmacology and Experimental Therapeutics 230(3): 558-568
Handley, D.A.; Van Valen, R.G.; Melden, M.K.; Houlihan, W.J.; Saunders, R.N. 1988: Biological effects of the orally active platelet activating factor receptor antagonist SDZ 64-412 Journal of Pharmacology and Experimental Therapeutics 247(2): 617-623
Kohli, J.D.; Goldberg, L.I.; Volkman, P.H.; Cannon, J.G. 1978: N,N-Di-n-propyl dopamine: a qualitatively different dopamine vascular agonist Journal of Pharmacology and Experimental Therapeutics 207(1): 16-22
Yamazaki, M.; Asakura, H.; Aoshima, K.; Saito, M.; Jokaji, H.; Uotani, C.; Kumabashiri, I.; Morishita, E.; Ikeda, T.; Matsuda, T. 1994: Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats Thrombosis and Haemostasis 72(3): 392-396
Wittenberg, C.; Rosenfeld, J.B. 1992: Long-term antihypertensive and renal effects of isradipine in hypertensive patients with normal and reduced renal function Journal of Cardiovascular Pharmacology 19(Suppl 3): S93-S95
Strandhoy, J.W.; Morris, M.; Buckalew, V.M. 1982: Renal effects of the antihypertensive, guanabenz, in the dog Journal of Pharmacology and Experimental Therapeutics 221(2): 347-352
Cook, N.S.; Bruttger, O.; Pally, C.; Hagenbach, A. 1993: The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active Thrombosis and Haemostasis 70(5): 838-847